In the BioHarmony Drug Report Database

"Preview" Icon

Neostigmine

Bloxiverz, Neostigmine Methylsulfate (neostigmine) is a small molecule pharmaceutical. Neostigmine was first approved as Bloxiverz on 2013-05-31. It is used to treat drug-induced abnormalities, myasthenia gravis, urinary bladder diseases, and urinary retention in the USA. It is known to target acetylcholinesterase.

 

Trade Name

 

Bloxiverz, Neostigmine Methylsulfate
 

Common Name

 

neostigmine
 

ChEMBL ID

 

CHEMBL278020
 

Indication

 

drug-induced abnormalities, myasthenia gravis, urinary bladder diseases, urinary retention
 

Drug Class

 

Cholinesterase inhibitors (physostigmine type)

Image (chem structure or protein)

Neostigmine structure rendering